Keep an eye out for these three themes as Big Pharma companies report their earnings.
Slowing sales for two top-selling therapies may mean that competitors gained ground last month.
No biotech experience required.
Bristol-Myers Squibb and Exelixis slug it out against Novartis.
Cancer immunotherapy is one of the hottest areas of cancer research these days, and the market looks to be worth billions. Which big pharma do we think will be the biggest winner in the space?
This simple fundamental metric says you might be overpaying for shares of most Big Pharma stocks.
Merck may be at the forefront of cancer care innovation, but an EU regulatory agency decided not to play "NICE" when it came to drug pricing.
The markets have been on a roller coaster-like ride over the past few weeks. Here are five dividend stocks that could anchor your portfolio during these turbulent times.
Bristol-Myers Squibb and GlaxoSmithKline are two Big Pharmas headed in opposite directions.
Bristol-Myers Squibb and Merck are two top dogs when it comes to dividend-paying healthcare stocks. Here's a look at which stock offers investors the better opportunity going forward.